Tan J, Li W, Wang P. Telomerase reverse transcriptase promoter-dr-iven expression of iodine pump genes for targeted radioiodinetherapy？of malignant glioma cells[J]. Chin J Cancer, 2011, 30(8)：574-580. [2] Shen CX, Wen Z, Qian YH, et al. Targeted gene therapy of nasopha-ryngeal cancer in vitro and in vivo by enhanced thymidine kinase expression driven by human TERT promoter and CMV enhancer[J]. J Exp Clin Cancer Res, 2010, 29：94. [3] Konopka K, Spain C, Yen A, et al. Correlation between the levels of survivin and survivin promoter-driven gene expression in cancer and non-cancer cells[J]. Cell Mol Biol Lett, 2009, 14(1)：70-89. [4] Qiu X, Zhu X, Zhang L, et al. Human epithelial cancers secrete immunoglobulin g with unidentified specificity to promote growth and survival of tumor cells[J]. Cancer Res, 2003, 63(19)：6488-6495. [5] Zhu X, Wu L, Zhang L, et al. Distinct regulatory mechanism of immunoglobulin gene transcription in epithelial cancer cells[J]. Cell Mol Imunol, 2010, 7(4)：279-286. [6] Chen KH, Guo X, Ma D, et al. Dysregulation of HSG triggers vascular proliferative disorders[J]. Nat Cell Biol, 2004, 6(9)：872-883. [7] Wu L, Li Z, Zhang Y, et al. Adenovirus-expressed human hyperplasia suppressor gene induces apoptosis in cancer cells[J]. Mol Cancer Ther, 2008, 7(1)：222-232. [8] Wang W, Zhu F, Wang S, et al. HSG provides antitumor efficacy on hepatocellular carcinoma both in vitro and in vivo[J]. Oncol Rep, 2010, 24(1)：183-188. [9] 戴益民.靶向化疗：基因治疗研究的新热点[J].世界华人消化杂志, 1999, 7(6)：469-472. [10] Onimaru M, Ohuchida K, Mizumoto K, et al. hTERT-promoter-dependent oncolytic adenovirus enhances the transduction and therapeutic efficacy of replication-defective adenovirus vectors in pancreatic cancer cells[J]. Cancer Sci, 2010, 101(3)：735-742. [11] Xie X, Hsu JL, Choi MG, et al. A novel hTERT promoter-driven E1A therapeutic for ovarian cancer[J]. Mol Cancer Ther, 2009, 8(8)：2375-2382. [12] 张鸽文, 刘霆, 王志明.肝细胞癌新型靶向基因治疗体系的构建及应用研究[J].生物医学工程学杂志, 2012, 29(3)：564-567. [13] Li YH, Jin LF, Du LF, et al. Enhancing HSP70-ShRNA transfection in 22RV1 prostate cancer cells by combination of sonoporation, liposomes and HTERT/CMV chimeric promoter[J]. Int J Oncol, 2013, 43(1)：151-158.
